---
layout: minimal-medicine
title: Isatuximab
---

# Isatuximab
### Generic Name
Isatuximab

### Usage
Isatuximab is a medication used to treat multiple myeloma, a type of blood cancer affecting plasma cells in the bone marrow.  It's specifically indicated for adult patients with multiple myeloma who have already received at least two prior therapies, including lenalidomide and a proteasome inhibitor.  It's used in combination with other drugs, such as pomalidomide and dexamethasone, or carfilzomib and dexamethasone, depending on the patient's treatment history and condition.  Isatuximab targets CD38, a protein found on the surface of myeloma cells, leading to their destruction.  The drug's primary use is in the treatment of relapsed or refractory multiple myeloma, meaning myeloma that has returned after treatment or hasn't responded to previous treatments.

### Dosage
Isatuximab is administered intravenously (IV). Dosage is calculated based on the patient's actual body weight.  Premedications are crucial before each infusion to minimize potential side effects.

**Multiple Myeloma (Relapsed or Refractory):**

* **Cycle 1:** 10 mg/kg on days 1, 8, 15, and 22 of a 28-day cycle. This is given in combination with either pomalidomide and dexamethasone or carfilzomib and dexamethasone.
* **Cycle 2 and beyond:** 10 mg/kg on days 1 and 15 of a 28-day cycle, continuing until disease progression or unacceptable toxicity.  The combination therapy with pomalidomide or carfilzomib and dexamethasone continues concurrently.

**Premedications:**  Before each Isatuximab infusion, premedications are typically given 15-60 minutes beforehand. These usually include:

* Dexamethasone (dosage varies depending on the combined therapy used)
* Acetaminophen
* An H2 antagonist
* Diphenhydramine (Intravenous route is preferred, especially for the first four infusions)

**Dosage Adjustments:** No dosage adjustments are generally needed for patients with hepatic (liver) or renal (kidney) impairment.  However, dosage modifications may be necessary based on the severity of side effects such as neutropenia (low white blood cell count) and infusion reactions.  Specific adjustments should be guided by a healthcare professional.  In cases of severe infusion reactions, the infusion may need to be temporarily halted or permanently discontinued.


### Side Effects

**Common Side Effects (>10%):**

* Fatigue
* Hypertension (high blood pressure)
* Diarrhea
* Nausea
* Vomiting
* Anemia (low red blood cell count)
* Febrile neutropenia (fever with low neutrophil count)
* Lymphocytopenia (low lymphocyte count)
* Neutropenia (low neutrophil count)
* Neutropenic infection (infection due to low neutrophils)
* Thrombocytopenia (low platelet count)
* Bronchitis
* Cough
* Dyspnea (shortness of breath)
* Pneumonia
* Upper respiratory tract infection
* Infection
* Infusion-related reactions


**Less Common, but Serious Side Effects:**

* Cardiac failure
* Skin cancers
* Other secondary malignancies
* Anaphylaxis (severe allergic reaction)
* Angioedema (swelling)
* Cytokine release syndrome


If you experience any side effects, particularly serious ones, contact your healthcare provider immediately.

### How it Works
Isatuximab is a monoclonal antibody that targets CD38, a protein present on the surface of multiple myeloma cells and other cells in the body. By binding to CD38, Isatuximab triggers several mechanisms that lead to the death of myeloma cells. These include:

* **Antibody-dependent cell-mediated cytotoxicity (ADCC):**  Isatuximab marks the myeloma cells for destruction by immune cells.
* **Antibody-dependent cellular phagocytosis (ADCP):** Immune cells engulf and destroy the myeloma cells.
* **Complement-dependent cytotoxicity (CDC):** The complement system, part of the immune system, is activated to destroy the myeloma cells.
* **Direct cell death (apoptosis):** Isatuximab directly induces the death of myeloma cells.

Additionally, Isatuximab can activate natural killer cells and suppress regulatory T-cells, further enhancing its anti-cancer effects.

### Precautions
* **Hypersensitivity:** Isatuximab is contraindicated in patients with severe hypersensitivity to the drug or its components.
* **Infusion Reactions:**  Serious infusion-related reactions, including anaphylaxis, can occur. Close monitoring during infusions is essential.
* **Neutropenia:** Isatuximab can cause neutropenia, increasing the risk of infections. Regular blood counts are needed.
* **Second Primary Malignancies:** There's an increased risk of developing other cancers.
* **Pregnancy and Breastfeeding:** Isatuximab can harm a developing fetus, and use during pregnancy is contraindicated.  Effective contraception is recommended for women of reproductive age. Breastfeeding is not recommended during treatment.
* **Drug Interactions:** Isatuximab may interfere with certain blood tests, potentially leading to false positive results.


### FAQs

**Q: How is Isatuximab stored?**  Follow the specific storage instructions provided by your pharmacist.  Generally, it should be refrigerated.

**Q: How long does it take to see results?**  The response to Isatuximab varies among patients.  It may take several weeks or months to observe noticeable effects.

**Q: Can I drive while taking Isatuximab?** Fatigue is a common side effect. If you feel fatigued, avoid driving or operating heavy machinery.

**Q: What should I do if I miss a dose?** Contact your healthcare provider immediately for guidance. Do not attempt to adjust your dosage independently.

**Q: Are there any long-term effects?** The long-term effects of Isatuximab are still being studied.  Regular monitoring is important to detect and manage any potential long-term issues.

**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult with a healthcare professional before starting or changing any medication.  They can assess your specific medical condition and determine the appropriate dosage, treatment plan, and monitoring schedule for you.
